May 13 that the Phase 2a results of an oral alpha 4 integrin antagonist.

With this partnership, we’ve rounded out our strategy in ophthalmology to add generics, branded and over-the-counter pharmaceuticals.’ Les Kaplan, Ph.D., Executive Chairman of Aciex Therapeutics, Inc., stated: ‘Aciex is excited to have Akorn simply because a strategic investor inside our business. Along with capital, they provide complementary experience that we believe can help accelerate the development of our pipeline of innovative ophthalmic items’. Â.. Ajinomoto announces Phase 2a results of oral alpha 4 integrin antagonist AJM300 in ulcerative colitis patients Ajinomoto Pharmaceuticals Co., Ltd. announced on, may 13 that the Phase 2a results of an oral alpha 4 integrin antagonist, AJM300, in individuals with ulcerative colitis had been shown in the Joint Presidential Plenary Program at Digestive Disease Week 2014 held Might 3 – 6 in Chicago, IL, USA.He has done what so many of the experts have stated couldn’t be done, finding a natural, drug-free method to conquer Bipolar disorder and steer clear of the discomfort suffered daily by millions. Now he wants to talk about his story to help inspire others to fight back!com, Organic Food News Today, and interviews in over 30 radio shows in the united states, Paul Huljich’s message is starting to change the way in which we regard mental disease and its own stigmas.’.

Acyclovir reduces occurrence of HSV-2 genital ulcers but will not affect HIV transmission Study from a five-12 months international clinical study demonstrates acyclovir, a commonly prescribed medication used to suppress symptoms of the herpes simplex virus, does not affect HIV transmitting by people with both viruses.